Repurposing Anticancer Drugs for the Management of COVID-19

Since its outbreak in the last December, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has rapidly spread worldwide at a pandemic proportion, thus regarded as a global public health emergency. The existing therapeutic options for COVID-19 beyond the intensive supportive care are limited, with an undefined or modest efficacy reported so far. Drug repurposing represents an enthusiastic mechanism to use approved drugs outside the scope of their original indication and accelerate the discovery of new therapeutic options.

Source: European Journal of Cancer - September 21, 2020 Category: Cancer & Oncology Authors: Khalid El Bairi, Dario Trapani, Angelica Petrillo, C écile Le Page, Hanaa Zbakh, Bruno Daniele, Rhizlane Belbaraka, Giuseppe Curigliano, Said Afqir Tags: Review Source Type: research